Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Off-the-shelf NK cell therapies: Artiva closes $78m Series A round

Artiva is working on bringing off-the-shelf NK cell therapies to cancer patients, supported by the manufacturing expertise of GC LabCell. To fund Artiva’s progression of three lead candidates to clinical trials, the company has raised $78m in a Series A round.

Close
Close
Close

Go Top